Bio-Connect
The data was published in the 2019 in J Exp Clin Cancer Res. PMID: 30961670
The data was published in the 2019 in J Exp Clin Cancer Res. PMID: 30961670
The data was published in the 2019 in J Exp Clin Cancer Res. PMID: 30961670

JAK1 (phospho Tyr1022/1023) antibody

GTX25493
GeneTex
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
Product group Antibodies
TargetJAK1
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    JAK1 (phospho Tyr1022/1023) antibody - Orthogonal Validated
  • Delivery Days Customer
    9
  • Application Supplier Note
    ICC/IF: 1:250. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    ImmunoFluorescence, Western Blot, ImmunoCytoChemistry
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Conjugate
    Unconjugated
  • Gene ID3716
  • Target name
    JAK1
  • Target description
    Janus kinase 1
  • Target synonyms
    AIIDE, JAK1A, JAK1B, JTK3, tyrosine-protein kinase JAK1
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDP23458
  • Protein Name
    Tyrosine-protein kinase JAK1
  • Scientific Description
    This gene encodes a membrane protein that is a member of a class of protein-tyrosine kinases (PTK) characterized by the presence of a second phosphotransferase-related domain immediately N-terminal to the PTK domain. The encoded kinase phosphorylates STAT proteins (signal transducers and activators of transcription) and plays a key role in interferon-alpha/beta and interferon-gamma signal transduction. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016]
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis.
    Read more
  • Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. Shen M et al., 2019 Apr 8, J Exp Clin Cancer Res
    Read more